Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
December 17 2024 - 4:00PM
UK Regulatory
Molecular Partners to Present at JP Morgan Healthcare Conference
and Baader Helvea Swiss Equities Conference in January
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass.,
Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN;
NASDAQ: MOLN), a clinical-stage biotech company developing a new
class of custom-built protein drugs known as DARPin therapeutics
(“Molecular Partners” or the “Company”), today announced it will
attend and present the Company’s latest developments and outlook
for 2025 at two upcoming investor conferences in January.
Baader Helvea Swiss Equities Conference, taking
place January 8-10 in Bad Ragaz, Switzerland
Chief Operating Officer Alexander Zürcher to present on
Wednesday, January 8 at the Grand Resort Bad Ragaz.
43rd Annual
JP Morgan Healthcare Conference, January 13-16 in San
Francisco, CA, USA.
Chief Executive Officer Patrick Amstutz to present on Wednesday,
January 15 at 9:00am PT (6:00pm CET) in the Elizabethan A ballroom
at the Westin, St. Francis.
All webcast presentations will be made available on the
Molecular Partners website.
About Molecular Partners AG
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage
biotech company pioneering the design and development of DARPin
therapeutics for medical challenges other drug modalities cannot
readily address. The Company has programs in various stages of
pre-clinical and clinical development, with oncology as its main
focus. Molecular Partners leverages the advantages of DARPins to
provide unique solutions to patients through its proprietary
programs as well as through partnerships with leading
pharmaceutical companies. Molecular Partners was founded in 2004
and has offices in both Zurich, Switzerland and Concord, MA, USA.
For more information, visit www.molecularpartners.com and find us
on LinkedIn and Twitter / X @MolecularPrtnrs
For further details, please contact:
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management &
Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995, as amended, including without limitation: implied and
express statements regarding the clinical development of Molecular
Partners’ current or future product candidates; expectations
regarding timing for reporting data from ongoing clinical trials or
the initiation of future clinical trials; the potential therapeutic
and clinical benefits of Molecular Partners’ product candidates and
its RDT and Switch-DARPin platforms; the selection and development
of future programs; Molecular Partners’ collaboration with Orano
Med including the benefits and results that may be achieved through
the collaboration; and Molecular Partners’ expected business and
financial outlook, including anticipated expenses and cash
utilization for 2024 and its expectation of its current cash runway
and the expected use of proceeds from the underwritten offering.
These statements may be identified by words such as “aim”,
“expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”,
“will” and similar expressions, and are based on Molecular
Partners’ current beliefs and expectations. These statements
involve risks and uncertainties that could cause actual results to
differ materially from those reflected in such statements. Some of
the key factors that could cause actual results to differ from
Molecular Partners’ expectations include its plans to develop and
potentially commercialize its product candidates; Molecular
Partners’ reliance on third party partners and collaborators over
which it may not always have full control; Molecular Partners’
ongoing and planned clinical trials and preclinical studies for its
product candidates, including the timing of such trials and
studies; the risk that the results of preclinical studies and
clinical trials may not be predictive of future results in
connection with future clinical trials; the timing of and Molecular
Partners’ ability to obtain and maintain regulatory approvals for
its product candidates; the extent of clinical trials potentially
required for Molecular Partners’ product candidates; the clinical
utility and ability to achieve market acceptance of Molecular
Partners’ product candidates; the potential that Molecular
Partners’ product candidates may exhibit serious adverse,
undesirable or unacceptable side effects; the impact of any health
pandemic, macroeconomic factors and other global events on
Molecular Partners’ preclinical studies, clinical trials or
operations, or the operations of third parties on which it relies;
Molecular Partners’ plans and development of any new indications
for its product candidates; Molecular Partners’ commercialization,
marketing and manufacturing capabilities and strategy; Molecular
Partners’ intellectual property position; Molecular Partners’
ability to identify and in-license additional product candidates;
unanticipated factors in addition to the foregoing that may impact
Molecular Partners’ financial and business projections and
guidance; and other risks and uncertainties set forth in Molecular
Partners’ Annual Report on Form 20-F for the year ended December
31, 2023 and other filings Molecular Partners makes with the SEC
from time to time. These documents are available on the Investors
page of Molecular Partners’ website at www.molecularpartners.com.
In addition, this press release contains information relating to
interim data as of the relevant data cutoff date, results of which
may differ from topline results that may be obtained in the future.
Any forward-looking statements speak only as of the date of this
press release and are based on information available to Molecular
Partners as of the date of this release, and Molecular Partners
assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Molecular Partners (LSE:0QXX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Molecular Partners (LSE:0QXX)
Historical Stock Chart
From Jan 2024 to Jan 2025